Add like
Add dislike
Add to saved papers

Malignant Melanoma Presenting as Thoracic Midline Malignancy: Clinicopathologic and Molecular Features.

Because of rarity, clinicopathologic and genomic profiles of noncutaneous malignant melanoma (MM) are not well characterized. In this study, we provide a detailed evaluation of 6 cases of MM presenting as thoracic midline malignancy. The tumors occurred in 6 white patients (5 males and 1 female; medium age, 71.5 y; range, 55 to 81 y). At presentation, the disease was confined to the chest (6/6) with 4 cases subsequently showing brain metastasis. All 6 tumors featured epithelioid and 1 case also spindle cell morphology. Three of 6 tumors had melanin and all 6 expressed melanocytic markers. Molecular characterization showed 2 of 6 tumors with BRAF"hot spot" genetic alterations (both with BRAFV600K) and 1 with NF1mutation. All 6 patients died of the disease within 1 year (mean survival, 4.8 mo). One patient showed a partial response to BRAF inhibitor. Our study shows that MM in this location has a spectrum of genetic alterations. The findings highlight the need for comprehensive next generation sequencing-based molecular testing to optimize targeted therapies of this aggressive malignancy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app